Trulieve Cannabis Corp. (CSE:TRUL) shares have continued their recent momentum with a 28% gain in the last month alone. But the last month did very little to improve the 53% share price decline over the last year.
Although its price has surged higher, it’s still not a stretch to say that Trulieve Cannabis’ price-to-sales (or “P/S”) ratio of 0.8x right now seems quite “middle-of-the-road” compared to the Pharmaceuticals industry in Canada, where the median P/S ratio is around 0.7x. While this might not raise any eyebrows, if the P/S ratio is not justified investors could be missing out on a potential opportunity or ignoring looming disappointment.
Check out our latest analysis for Trulieve Cannabis
